BioPharmSignal logoBioPharmSignal

Biotech News

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Kiora Pharmaceuticals (KPRX)Kiora PharmaceuticalsFinancing

KPRX (KPRX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is kprx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Related news

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

KPRXKiora Pharmaceuticals2025-12-01 11:45 EST

Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds

OTLKOutlook2026-05-28 20:00 EST

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

OTLKOutlook2026-04-23 20:05 EST

Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering

MGTXMeiraGTx2026-04-16 11:48 EST

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

VRDNViridian Therapeutics2021-09-23 20:01 EST

Viridian Therapeutics Announces Closing of Public Offering of Shares of Common Stock and Preferred Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

VRDNViridian Therapeutics2021-09-21 04:22 EST

Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock and Preferred Stock

LENZLenz Therapeutics Inc2026-06-24 12:30 EST

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

View all latest news

Kiora Pharmaceuticals

Kiora Pharmaceuticals is a biotechnology company focused on ophthalmology and retinal disease. Its story is centered on developing treatments for eye diseases where local delivery and specialized biology matter.

Recent company news

KPRXKiora Pharmaceuticals2026-07-02 11:00 EST

Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium

KPRXKiora Pharmaceuticals2026-06-18 11:00 EST

Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model

KPRXKiora Pharmaceuticals2026-05-08 11:00 EST

Kiora Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

KPRXKiora Pharmaceuticals2026-04-14 11:00 EST

Kiora's Phase 1 ABACUS Study of KIO-301 in Retinitis Pigmentosa Published in Nature Medicine; Phase 2 Trial Underway

KPRXKiora Pharmaceuticals2026-04-07 11:00 EST

Kiora Pharmaceuticals Announces Private Placement for Up to $24 Million Led by Perceptive Advisors

Stock data

Close
2.54 USD
Market cap
12.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States